The FTC's decision to pause its challenge against Amgen's proposed acquisition of Horizon Therapeutics has led to an increase in Horizon's share price. This is because the pause could be seen as a positive sign for the acquisition to go through, which would likely be beneficial for Horizon's shareholders.